STING1 and neoplasm: Furthermore, tumor-derived DNA or cGAMP activates DCs via the cGAS–STING pathway, inducing the production of type I IFNs that enhance the cross-presentation ability of DCs and improve tumor clearance via adaptive immunity (Diamond et al., 2011; Fuertes et al., 2011).